n CME : Your SA Journal of CPD - Lipid-modifying therapy

Volume 27, Issue 3
  • ISSN : 0256-2170



The ultimate aim of lipid-modifying therapy is cardiovascular risk reduction for most patients, while patients with severe hypertriglyceridaemia are primarily treated to reduce the risk of acute pancreatitis. Patients and doctors are pleased to see improved lipid parameters, but without accompanying risk reduction this would be a somewhat hollow victory. Treatment decisions are therefore based on an assessment of risk, rather than on lipid levels alone. The article titled 'A clinical approach to dyslipidaemia' provides more information on risk assessment and indications for lipid-modifying therapy.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error